Unleash Raises $35M Led by One Peak to Help Enterprises Ship AI-driven Software Faster, Safer, and Smarter
4.3.2026 15:00:00 CET | Business Wire | Press Release
Unleash, the open-source FeatureOps company, today announced a $35 million Series B financing led by One Peak, with participation from existing investors Spark Capital, Frontline Ventures, and Firstminute Capital. The new funding will be used to accelerate product innovation and global expansion as enterprises confront the opportunities and risks of AI-accelerated software delivery.
AI has dramatically accelerated software development, creating a generational opportunity for anyone in an enterprise to turn ideas, prompts, and prototypes into applications. But AI has also outpaced the systems designed to control software delivery. DORA research shows that a 25% rise in AI adoption correlates with a 7% drop in software stability. Enterprises are shipping code 2-3x faster with AI, yet outages caused by uncontrolled feature rollouts and missing kill switches are costing businesses millions in lost revenue, prolonged customer downtime, and brand damage. FeatureOps is emerging as the missing operational layer, giving enterprises real-time control over what turns on, who sees it, and how quickly it can be rolled back when AI-generated code moves faster than traditional governance can keep up.
“When AI-generated code is in production, and something breaks, every minute of downtime costs you revenue and customers,” said Egil Østhus, CEO and co-founder. “You need the ability to diagnose, fix, and recover immediately. The Unleash open-source FeatureOps platform gives you that control, and we’ve proven it works in the world’s most highly regulated industries."
The tension between speed and stability is increasingly felt inside engineering teams.
"Developers are still the ones who get called at 2 am when something goes wrong," said Ivar Østhus, CTO and creator of Unleash. “You've got engineers shipping faster than ever, but also more stressed than ever because they have less visibility into what's actually running in production. We give them that visibility so they can still move fast, but they know exactly what’s live and can release it or kill it in seconds.”
Designed for high-compliance environments, Unleash is the world's largest open-source FeatureOps platform with over 13,000 GitHub stars and 40 million downloads. As highlighted at Unleash’s recent user conference, by providing a transparent, enterprise-grade framework for FeatureOps, Unleash has become a system of record for organizations like Prudential, Lloyds Banking Group, Wayfair and Lenovo who must balance AI-driven speed with enterprise-grade governance at scale:
“At Wayfair, code velocity has exploded. Developers are pushing huge amounts of AI-assisted code, and reviews are moving to production quicker than ever. But here's the paradox: speed is up, but reliability is down. AI is accelerating risk because it is almost impossible for QA teams to keep up. This is where FeatureOps comes in. At our scale, a single unchecked release could cause major revenue loss,” said Kiriti Dhanai, Site Reliability Engineer, Wayfair at UnleashCon.
With this Series B, Unleash will accelerate its investment in autonomous end-to-end feature management and full-stack experimentation, providing the industry’s first fail-safe release infrastructure to bridge the gap between AI speed and human responsibility.
“AI is transforming the way and speed at which software is built, and the enterprises that win will be the ones that can harness that speed effectively,” said Christoph Mayer, Partner at One Peak. “Unleash provides the control layer that allows companies to innovate faster while maintaining governance and reliability. That combination is incredibly powerful.”
The Series B brings Unleash’s total funding to $51.5M. Since its Series A in 2022, Unleash has:
- Doubled annual recurring revenue for the last three years with an NRR of 140%.
- Crossed the 500 paying customers mark.
- Exceeded 40 million total downloads, a significant increase in global footprint.
- Surpassed 13,000 GitHub stars, maintaining its position as the world’s largest open-source feature management ecosystem.
- Powered billions of daily feature flag evaluations for organizations worldwide.
- Rapidly expanded its enterprise customer base, with a focus on highly regulated sectors including Financial Services and Global Retail.
- Established FeatureOps as a critical category for organizations scaling AI-generated software.
Additional resources:
- Read more about Unleash’s vision for FeatureOps in an AI-driven world.
- Listen to talks from customers like Prudential, Lloyds Banking Group, Wayfair, and Lenovo at UnleashCon and related customer events.
- Learn more about FeatureOps at https://featureops.io/.
About Unleash
Unleash is the enterprise FeatureOps platform that brings Autonomous Feature Management to modern software delivery. Built for the AI era, Unleash gives organizations real-time control over how software behaves in production, enabling controlled releases, full-stack experimentation, and surgical rollbacks at scale. Trusted by enterprises including Lloyds Bank, Prudential, Wayfair, Lenovo, and Mercadona, Unleash supports the scale and operational complexity of the world’s largest and most innovative organizations.
About One Peak
One Peak is a leading growth equity firm with $4bn in assets under management that invests in technology companies in the scale-up phase. One Peak provides growth capital, operating expertise, and access to its extensive network of exceptional entrepreneurs, with a view to help transform innovative and rapidly growing businesses into lasting, category-defining leaders. In addition to Unleash, One Peak’s investments include Akur8, Ardoq, Cymulate, Datarails, Deepki, Docplanner, emnify, iplicit, Keepit, Lucca, Neo4j, PandaDoc, Sparta, and many others.
To learn more, visit www.onepeak.tech.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260304717368/en/
Contacts
For more information contact press@getunleash.io
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom